{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:46:29Z","timestamp":1793195189757,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T00:00:00Z","timestamp":1504742400000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.vaccine.2017.08.039","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T06:32:45Z","timestamp":1504247565000},"page":"5331-5338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2\u201317-year-old children with asplenia or splenic dysfunction: A phase 3 study"],"prefix":"10.1016","volume":"35","author":[{"given":"L.","family":"Szenborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.V.","family":"Osipova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Czajka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Kharit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Jackowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Borys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.08.039_b0005","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1128\/CMR.00048-09","article-title":"Infections of people with complement deficiencies and patients who have undergone splenectomy","volume":"23","author":"Ram","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2017.08.039_b0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1034\/j.1600-0609.2003.00158.x","article-title":"Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes","volume":"71","author":"Castagnola","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.vaccine.2017.08.039_b0015","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1067\/S0022-3476(03)00331-7","article-title":"Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination","volume":"143","author":"Adamkiewicz","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2017.08.039_b0020","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/bjs.6106","article-title":"Vaccination of asplenic or hyposplenic adults","volume":"95","author":"Mourtzoukou","year":"2008","journal-title":"Br J Surg"},{"key":"10.1016\/j.vaccine.2017.08.039_b0025","first-page":"1","volume":"59","author":"Nuorti","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2017.08.039_b0030","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/infdis\/jis212","article-title":"Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells","volume":"205","author":"Clutterbuck","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.039_b0035","series-title":"Vaccines","first-page":"531","article-title":"Pneumococcal conjugate vaccine and pneumococcal common protein vaccines","author":"Black","year":"2008"},{"key":"10.1016\/j.vaccine.2017.08.039_b0040","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1542\/peds.106.5.965","article-title":"Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group","volume":"106","author":"O'Brien","year":"2000","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.08.039_b0045","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/INF.0b013e31814614c6","article-title":"Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease","volume":"26","author":"Reinert","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.08.039_b0050","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.1016\/j.vaccine.2007.05.014","article-title":"Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine","volume":"25","author":"Smets","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.039_b0055","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10096-008-0523-5","article-title":"Immune response to the 7-valent pneumococcal conjugate vaccine in 30 asplenic children","volume":"27","author":"Mikoluc","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2017.08.039_b0060","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/pbc.25502","article-title":"13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6\u201317 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): results of a phase 3 study","volume":"62","author":"De Montalembert","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.vaccine.2017.08.039_b0065","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1586\/erv.09.113","article-title":"10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: synflorix","volume":"8","author":"Prymula","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.08.039_b0070","doi-asserted-by":"crossref","first-page":"e1001657","DOI":"10.1371\/journal.pmed.1001657","article-title":"Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial","volume":"11","author":"Tregnaghi","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2017.08.039_b0075","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0140-6736(12)61854-6","article-title":"Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial","volume":"381","author":"Palmu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.08.039_b0080","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-2600(14)70060-8","article-title":"Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study","volume":"2","author":"Domingues","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2017.08.039_b0085","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1016\/j.vaccine.2015.10.007","article-title":"Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study Group. Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease","volume":"33","author":"Verani","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.039_b0090","doi-asserted-by":"crossref","first-page":"e0120290","DOI":"10.1371\/journal.pone.0120290","article-title":"Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children\u2013a population-based study","volume":"10","author":"Jokinen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.08.039_b0095","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.vaccine.2015.06.104","article-title":"Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada","volume":"34","author":"De Wals","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.039_b0100","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1016\/j.vaccine.2015.04.005","article-title":"Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada","volume":"33","author":"Deceuninck","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.039_b0105","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1542\/peds.2010-1184","article-title":"Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine","volume":"128","author":"Ome\u00f1aca","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.08.039_b0110","doi-asserted-by":"crossref","first-page":"e5881","DOI":"10.1097\/MD.0000000000005881","article-title":"Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status","volume":"96","author":"Madhi","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.vaccine.2017.08.039_b0115","article-title":"Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered to children with sickle cell disease between 8 weeks and 2 years of age: a phase III, open, controlled study","author":"Sirima","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.08.039_b0120","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/CVI.13.3.356-360.2006","article-title":"Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera","volume":"13","author":"Henckaerts","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.08.039_b0125","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1128\/CVI.00289-09","article-title":"Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines","volume":"17","author":"Poolman","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.08.039_b0130","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/S0264-410X(00)00044-X","article-title":"Development of a multi-specificity opsonophagocytic killing assay","volume":"18","author":"Nahm","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.08.039_b0135","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1542\/peds.2007-0018","article-title":"Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life","volume":"121","author":"Adamkiewicz","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.08.039_b0140","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1086\/516781","article-title":"Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine","volume":"44","author":"Halasa","year":"2007","journal-title":"Clin Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17311271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17311271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T11:28:43Z","timestamp":1536060523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17311271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":28,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0264410X17311271"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2\u201317-year-old children with asplenia or splenic dysfunction: A phase 3 study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.08.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 GlaxoSmithKline SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}